These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26681779)

  • 1. Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way?
    Landovitz RJ; Grinsztejn B
    J Infect Dis; 2016 May; 213(10):1519-20. PubMed ID: 26681779
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiretroviral pre-exposure prophylaxis for HIV prevention is highly effective in community settings.
    Bazzi AR
    Evid Based Med; 2016 Jun; 21(3):99. PubMed ID: 27029888
    [No Abstract]   [Full Text] [Related]  

  • 3. The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV Prevention.
    Jain S; Krakower DS; Mayer KH
    Clin Infect Dis; 2015 Jun; 60 Suppl 3(Suppl 3):S200-4. PubMed ID: 25972505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing HIV Prevention with Injectable Preexposure Prophylaxis.
    Abdool Karim Q
    N Engl J Med; 2021 Aug; 385(7):652-653. PubMed ID: 34379927
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project.
    Eakle R; Gomez GB; Naicker N; Bothma R; Mbogua J; Cabrera Escobar MA; Saayman E; Moorhouse M; Venter WDF; Rees H;
    PLoS Med; 2017 Nov; 14(11):e1002444. PubMed ID: 29161256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [PrEP for HIV prevention, major tool of the global diversified prevention strategy].
    Slama L
    Rev Prat; 2021 Nov; 71(9):957-959. PubMed ID: 35147307
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How much could long-acting PrEP cost in South Africa?
    Mudimu E; Bershteyn A
    Lancet HIV; 2022 Dec; 9(12):e814-e815. PubMed ID: 36356602
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges.
    Agrahari V; Anderson SM; Peet MM; Wong AP; Singh ON; Doncel GF; Clark MR
    Expert Opin Drug Deliv; 2022 Oct; 19(10):1365-1380. PubMed ID: 36252277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.
    Lykins WR; Luecke E; Johengen D; van der Straten A; Desai TA
    Drug Deliv Transl Res; 2017 Dec; 7(6):805-816. PubMed ID: 28612340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence supports use of on-demand PrEP for HIV prevention.
    Chow EPF; Fairley CK
    Lancet HIV; 2022 Aug; 9(8):e524-e526. PubMed ID: 35772418
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacists and the next generation of HIV pre-exposure prophylaxis.
    Griffith K; Romanelli F
    J Am Pharm Assoc (2003); 2022; 62(5):1542-1545. PubMed ID: 35961938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting preexposure prophylaxis in low- and middle-income countries: key considerations for implementation.
    Kaewpoowat Q; Chariyalertsak S; Phanuphak N; Ramautarsing RA
    Curr Opin HIV AIDS; 2022 May; 17(3):135-144. PubMed ID: 35439788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preexposure Prophylaxis in the United States: An Evolving HIV Prevention Opportunity.
    Goldschmidt RH
    Clin Infect Dis; 2017 Jan; 64(2):150-151. PubMed ID: 27986676
    [No Abstract]   [Full Text] [Related]  

  • 15. Community Federally Qualified Health Centers as Homes for HIV Preexposure Prophylaxis: Perspectives from South Florida.
    Doblecki-Lewis S; Jones D
    J Int Assoc Provid AIDS Care; 2016 Nov; 15(6):522-528. PubMed ID: 27502831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-exposure prophylaxis for South African adolescents: What evidence?
    Bekker LG; Gill K; Wallace M
    S Afr Med J; 2015 Nov; 105(11):907-11. PubMed ID: 26632316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Potential of Long-Acting, Injectable PrEP, and Impediments to its Uptake.
    Miller AS; Krakower DS; Mayer KH
    J Urban Health; 2023 Feb; 100(1):212-214. PubMed ID: 36630070
    [No Abstract]   [Full Text] [Related]  

  • 18. The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth.
    Montgomery ET; Atujuna M; Krogstad E; Hartmann M; Ndwayana S; OʼRourke S; Bekker LG; van der Straten A; Minnis AM
    J Acquir Immune Defic Syndr; 2019 Apr; 80(5):542-550. PubMed ID: 30865050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New preexposure prophylaxis options need updated counseling approaches: reframing 'risk' in HIV prevention counseling for young sexual and gender minorities of color.
    Maragh-Bass AC; Stoner MCD; Castellanos-Usigli A; Agarwal H; Katz AWK; Patani H; Sukhija-Cohen A; Campbell L; Arreola S; Saberi P
    AIDS; 2023 Jul; 37(9):1361-1366. PubMed ID: 37070546
    [No Abstract]   [Full Text] [Related]  

  • 20. Circulating HIV type 1 drug resistance will have limited impact on the effectiveness of preexposure prophylaxis among young women in Zimbabwe.
    van de Vijver DA; Derdelinckx I; Boucher CA
    J Infect Dis; 2009 May; 199(9):1310-7. PubMed ID: 19301982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.